William A. Werbel, MD, PhD is an Associate Professor of Medicine in the Division of Infectious Diseases at Johns Hopkins University School of Medicine, with a joint appointment in Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He serves as the Associate Director for Epidemiology and Quantitative Sciences in the Johns Hopkins Transplant Research Center.
Dr. Werbel's research focuses on optimizing protection against infections for immunosuppressed persons using a combination of epidemiological and laboratory approaches. He leads clinical trials and national studies of respiratory viral vaccinations for transplant recipients and other immunosuppressed populations.
Following MD training at the University of Michigan and internal medicine residency and chief residency at Northwestern University, he completed fellowships in infectious diseases as well as a PhD in Clinical Investigation at Johns Hopkins. His work bridges clinical practice and translational research to improve outcomes for some of the most vulnerable patient populations.
Specialized care for transplant recipients navigating complex infectious disease risks during immunosuppression.
Managing infectious complications in cancer patients undergoing immunosuppressive therapies and treatments.
Leading clinical trials to optimize vaccination strategies for patients whose immune systems are compromised.
Applying epidemiological methods to understand and reduce infection risk in vulnerable populations.
Studying respiratory virus transmission, prevention, and treatment in high-risk immunocompromised patients.
Bridging bench-to-bedside research to develop improved diagnostic and therapeutic approaches for immunosuppressed patients.
Evidence-based approaches to optimizing vaccine timing, dosing, and selection for transplant recipients and cancer patients with compromised immune systems.
How cancer therapies affect the immune system's ability to fight infections, and what survivors need to know about immune reconstitution and long-term protection.
Practical strategies for reducing infectious complications during and after cancer treatment, including prophylaxis, screening, and early intervention approaches.
Emerging findings from national vaccination studies and clinical trials that are shaping the future of infection prevention for immunocompromised populations.
Three days of physician-led sessions, survivor stories and community for patients, survivors, caregivers and clinicians at the Four Seasons Las Vegas.
Your gift keeps every guide, chat, and support call free. TCF is a 501(c)(3) nonprofit. Donations are tax-deductible.